These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

886 related articles for article (PubMed ID: 33216972)

  • 21. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-Based Treatment Approaches in Multiple Myeloma.
    Hosoya H; Sidana S
    Curr Hematol Malig Rep; 2021 Apr; 16(2):183-191. PubMed ID: 33730360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
    Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current antibody-based therapies for the treatment of multiple myeloma.
    Varga C; Waldschmidt JM; Gandolfi S; Richardson PG
    Clin Adv Hematol Oncol; 2020 Nov; 18(11):736-748. PubMed ID: 33406065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belantamab mafodotin for the treatment of multiple myeloma.
    Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
    Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
    D'Agostino M; Raje N
    Leukemia; 2020 Jan; 34(1):21-34. PubMed ID: 31780814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel approaches to the treatment of multiple myeloma.
    Maples KT; Scott SA; Lonial S
    Clin Adv Hematol Oncol; 2023 May; 21(5):247-256. PubMed ID: 37145495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
    Sanchez L; Dardac A; Madduri D; Richard S; Richter J
    Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bispecifics, trispecifics, and other novel immune treatments in myeloma.
    Lancman G; Richter J; Chari A
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):264-271. PubMed ID: 33275733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple Myeloma: The CAR T-cell Therapy Landscape.
    Cancer Discov; 2020 Feb; 10(2):OF6. PubMed ID: 31915196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
    Sunder-Plassmann V; Aksoy O; Lind J; Pecherstorfer M; Vallet S; Podar K
    Expert Opin Pharmacother; 2022 Aug; 23(12):1425-1444. PubMed ID: 35829636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
    Rees MJ; Kumar S
    Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
    DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
    Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
    Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
    J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
    Guo R; Lu W; Zhang Y; Cao X; Jin X; Zhao M
    Front Immunol; 2022; 13():839097. PubMed ID: 35320942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
    Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
    Front Immunol; 2021; 12():609421. PubMed ID: 33767695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.